KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Receivables (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Receivables for 17 consecutive years, with $472.5 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 1.48% to $472.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $472.5 million through Dec 2025, up 1.48% year-over-year, with the annual reading at $472.5 million for FY2025, 1.48% up from the prior year.
  • Receivables for Q4 2025 was $472.5 million at Bio-Rad Laboratories, roughly flat from $474.2 million in the prior quarter.
  • The five-year high for Receivables was $513.1 million in Q1 2023, with the low at $401.2 million in Q2 2021.
  • Average Receivables over 5 years is $461.5 million, with a median of $467.1 million recorded in 2023.
  • The sharpest move saw Receivables increased 18.91% in 2022, then fell 10.42% in 2024.
  • Over 5 years, Receivables stood at $425.7 million in 2021, then increased by 18.91% to $506.2 million in 2022, then dropped by 1.06% to $500.9 million in 2023, then fell by 7.05% to $465.6 million in 2024, then rose by 1.48% to $472.5 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $472.5 million, $474.2 million, and $478.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.